Skip to content
Review Open access

Pathophysiology and Contemporary Management Approaches in Age-Related Macular Degeneration

Unknown authors
Aug 2026 · CME journal. Geriatric medicine · Vol 18, pp. 111-115 · 0 citations

Abstract

Background: Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in the elderly, primarily affecting the macula. Objective: This review examines the pathophysiology of AMD, evaluates current treatment modalities, and highlights outcomes from ongoing management strategies. Methods: Relevant clinical studies, epidemiological data, and randomized clinical trials were reviewed to assess disease mechanisms and the efficacy of available therapies. Results: Oxidative stress, genetic susceptibility, and retinal pigment epithelium (RPE) dysfunction are central to AMD pathology. Anti-vascular endothelial growth factor (anti-VEGF) therapy significantly improves visual outcomes in neovascular (wet) AMD, whereas antioxidant supplementation offers limited benefit in dry AMD. Conclusion: AMD remains a significant public health concern. Anti-VEGF therapies have revolutionized the management of wet AMD, but preventive strategies and novel therapeutic approaches are essential to address the unmet needs in dry AMD.

Read PDF

Similar papers

Review Open access Sep 2026

SELECTED CONTEMPORARY THERAPEUTIC STRATEGIES FOR AGE-RELATED MACULAR DEGENERATION: EFFICACY, SAFETY, AND FUTURE DIRECTIONS

Age-related macular degeneration (AMD) is one of the leading causes of irreversible central vision impairment in older adults. The introduction of intravitreal vascular endothelial growth factor (VEGF) inhibitors has fundamentally changed the prognosis of neovascular AMD (nAMD). Contemporary research focuses both on ma...

Zuzanna Kordyś-Wyrobek, Marcelina Skajewska, Maciej Lazarek et al. · 0 citations
Review

Innovative Technologies

Zuzanna Kordyś-Wyrobek, Marcelina Skajewska, Maciej Lazarek et al. · 0 citations
Open access Oct 2026

Insights into the modulation of age‐related macular degeneration: Molecular and systems‐level perspectives

ENGLISH SUMMARY In developed countries, age‐related macular degeneration (AMD) is the leading cause of visual impairment in the aging population. Understanding of its pathogenesis is limited and the number of patients is predicted to continue rising. AMD is classified into two main forms: dry and neovascular AMD (dAMD...

Hanna Heloterä · 0 citations
Review Open access Aug 2026

[Glaucoma and age-related macular degeneration: challenges and prospects for prevention and treatment of combined pathology. Part 1. Epidemiology and pathogenesis].

Glaucoma and age-related macular degeneration are the leading causes of irreversible vision loss in individuals over 60 years of age. This review consolidates current data on the epidemiology, shared genetic factors, and pathophysiological mechanisms underpinning their coexistence, and outlines prospects for personaliz...

N. Kurysheva, E. V. Maslova · 0 citations
Review

Innovative Technologies in Social

N. Kornacka, K. Bednarski, Bartosz Zawadzki et al. · 0 citations
Review Open access Aug 2026

CURRENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPIES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A NARRATIVE REVIEW OF AVAILABLE AGENTS AND TREATMENT STRATEGIES

Background: Neovascular age-related macular degeneration (nAMD) is a leading cause of irreversible central vision loss in older adults. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has transformed disease management, but the expanding range of agents and evolving dosing strategies has compli...

Gabriela Luba, Wiktoria Napiórkowska, Aleksandra Izabela Masłowska et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.